Euroopa Liit - eesti - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - rinnanäärmed - antineoplastilised ained - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - kana - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Eesti - eesti - Ravimiamet

norameda uab - sunitiniib - kõvakapsel - 12,5mg 30tk; 12,5mg 28tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - sunitiniib - kõvakapsel - 25mg 14tk; 25mg 10tk; 25mg 7tk; 25mg 20tk; 25mg 21tk; 25mg 28tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - sunitiniib - kõvakapsel - 12,5mg 14tk; 12,5mg 30tk; 12,5mg 21tk; 12,5mg 7tk; 12,5mg 28tk; 12,5mg 10tk; 12,5mg 20tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - sunitiniib - kõvakapsel - 50mg 21tk; 50mg 10tk; 50mg 14tk; 50mg 20tk; 50mg 7tk; 50mg 28tk

Eesti - eesti - Ravimiamet

glaxosmithkline biologicals - tuulerõugete viirus, elus, nõrgestatud - süstelahuse pulber ja lahusti süstlis - 1annus 10tk; 1annus 1tk

Eesti - eesti - Ravimiamet

norameda uab - sunitiniib - kõvakapsel - 50mg 28tk; 50mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunoloogilised ained - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).